Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D07RDV
|
|||
Former ID |
DNC004034
|
|||
Drug Name |
Z-Ala-Leu-Phe-Agly-Ile-Val-OMe
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C39H57N7O9
|
|||
Canonical SMILES |
CCC(C)C(C(=O)NC(C(C)C)C(=O)OC)NC(=O)NNC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)OCC2=CC=CC=C2
|
|||
InChI |
1S/C39H57N7O9/c1-9-25(6)32(36(50)43-31(24(4)5)37(51)54-8)44-38(52)46-45-35(49)30(21-27-16-12-10-13-17-27)42-34(48)29(20-23(2)3)41-33(47)26(7)40-39(53)55-22-28-18-14-11-15-19-28/h10-19,23-26,29-32H,9,20-22H2,1-8H3,(H,40,53)(H,41,47)(H,42,48)(H,43,50)(H,45,49)(H2,44,46,52)
|
|||
InChIKey |
ONHOINLCWRTXCR-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Cathepsin B (CTSB) | Target Info | Inhibitor | [1] |
Cathepsin K (CTSK) | Target Info | Inhibitor | [1] | |
KEGG Pathway | Lysosome | |||
Osteoclast differentiation | ||||
Toll-like receptor signaling pathway | ||||
Rheumatoid arthritis | ||||
Antigen processing and presentation | ||||
NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
RANKL Signaling Pathway | ||||
IL2 Signaling Pathway | ||||
TCR Signaling Pathway | ||||
Reactome | Collagen degradation | |||
Degradation of the extracellular matrix | ||||
Activation of Matrix Metalloproteinases | ||||
Trafficking and processing of endosomal TLR | ||||
MHC class II antigen presentation | ||||
Assembly of collagen fibrils and other multimeric structures | ||||
WikiPathways | RANKL/RANK Signaling Pathway | |||
Osteoclast Signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.